Alopecia Areata Video Perspectives
Emma Guttman-Yassky, MD, PhD
Disclosures
Guttman-Yassky reports financial relationships with AbbVie, Almirall, Amgen, AnaptysBio, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Innovaderm, Janssen Biotech, Kyowa Kirin, LEO Pharma, Novartis, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB and Ventyx Biosciences.
October 11, 2023
1 min watch
Save
VIDEO: Lack of alopecia areata treatment options for pediatric patients
Transcript
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Challenges is that we don't have anything approved for any patients that have alopecia areata in pediatric patients. And that's the age group where we need the most treatments, both for mild alopecia areata but definitely for the moderate to severe patients.
